CN105126067A - Composition for reducing uric acid and application thereof - Google Patents
Composition for reducing uric acid and application thereof Download PDFInfo
- Publication number
- CN105126067A CN105126067A CN201510642189.9A CN201510642189A CN105126067A CN 105126067 A CN105126067 A CN 105126067A CN 201510642189 A CN201510642189 A CN 201510642189A CN 105126067 A CN105126067 A CN 105126067A
- Authority
- CN
- China
- Prior art keywords
- uric acid
- compositions
- patient
- leaf
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention relates to a composition for reducing uric acid and application thereof. Ocean fish oligopeptide powder, moringa oleifera leaf powder, acerola cherry concentrates and green plum extract are used as raw materials and matched with various edible auxiliary materials to prepare the composition. The composition is prepared from, by weight, 5-35% of ocean fish oligopeptide powder, 5-45% of moringa oleifera leaf powder, 2-15% of acerola cherry concentrates, 5-30% of green plum extract and the balance edible auxiliary materials. The food raw materials are selected and synergistically take effects by means of scientific compatibility, so that the composition is high in uric acid reducing speed, remarkable in effect, safe and free from side effects.
Description
Technical field
The invention belongs to health food field, be specifically related to a kind of composition and use thereof of uric acid resisting, particularly relate to a kind of food and new resource food composition and use thereof of uric acid resisting.
Background technology
Adult normal about produces uric acid 750mg every day, wherein 80% is endogenous, 20% is exogenous uric acid, these uric acid enter uric acid metabolism pond (being about 1200mg), uric acid about 60% in every day metabolic pool carries out metabolism, wherein 1/3 about 200mg is through intestinal catabolism, and 2/3 about 400mg through renal excretion, thus maintains the stable of uric acid level in body.The uricopoiesis that purine metabolic disturbance causes increases or underexcretion all can cause hyperuricemia.The morbidity of modern medicine clear and definite gout is directly related with hyperuricemia, is a kind of serious metabolic disease of harm humans health.Gouty arthritis causes urate deposition at joint capsule, synovial membrane, cartilage, kidney, subcutaneous, its hetero-organization and the one caused organizes disease damage and inflammatory reaction because uric acid in body increases.Blood uric acid rising is the key character of gouty arthritis.
Along with the raising of people's living standard, the change of dietary structure, the intake of sugar, albumen, fat obviously increases, and the sickness rate of gout increases year by year.At present, the measure for the treatment of gout mainly suppresses uricopoiesis and promotes urate excretion.Clinical commonly used drug has nonsteroidal anti-inflammatory agent, colchicine, glucocorticoid, probenecid, benzene Australia Ma Long, allopurinol, therapeutic effect is remarkable, but all there is toxic and side effects in various degree and untoward reaction in them, infringement liver, nervous system, cause skin allergy, life-threatening super quick allergy etc.But there is no toxic and side effects with the uric acid resisting product of raw-food material exploitation, thus there is the very high market advantage.
Having some is at present that raw material is to prepare the research of uric acid resisting product with food, such as, CN104758920A discloses a kind of gout health care product based on integration of edible and medicinal herbs, and it contains the oligomeric Gly-His-Lys of marine fish, Poria and Herba Lophatheri, and its weight ratio is 1:0.5-1.5:0.5-1.5; These ventilation health product effectively can suppress metabolic arthritis, and remove tophus, enhancing immunity, has immunity moderation power, the effect of uric acid resisting, and has no side effect.But it realizes that Level of Serum Uric Acid is normal and the ventilation stone removed cycle is longer, after edible 3 months, total effective rate only can reach 96.1%.CN104829743A discloses a kind of preparation method of Polysaccharides from Leaves of Moringa oleifera and the purposes on uric acid resisting thereof.The polysaccharide of obtained leaf of Moringa of the present invention has significant therapeutic effect to metabolic arthritis disease; this leaf of Moringa is by reducing the content of cholesterol, triacylglycerol, blood urea nitrogen, creatinine and xanthine oxidase thus reaching reduction uricopoiesis; simultaneously also can Direct Resolution uric acid; improve renal function, promote urate excretion, protect the functions such as blood vessel, be more conducive to the rehabilitation of Patients with Hyperuricemia.CN103637105A relates to a kind of cherry capsule, and it comprises Fructus Pruni pseudocerasi powder and Fructus Pruni pseudocerasi extractum, and the capsule product be made up of it is pure natural cherry fruit extract, and it has good effect to rheumatic lumbocrural pain pain, is particularly useful for metabolic arthritis and patient with gout.CN104824313A discloses a kind of fermented type green plum goods and the production technology thereof with plurality of health care functions, these green plum goods are made up of green plum, Folium camelliae assamicae, Folium Nelumbinis, Radix Glycyrrhizae compatibility, containing the abundant functional component such as organic acid, polysaccharide, Armeniaca mume Sieb. flavone, tea polyphenols, licoflavone, nuciferine, the plurality of health care functions of cleaning intestinal, lowering blood-fat and reducing weight, reduction uric acid, prevention cardiovascular and cerebrovascular disease etc. can be played.
Although existing all multi-products adopt raw-food material to realize effect of uric acid resisting at present, but, when it is applied clinically, ubiquity the deficiencies such as treatment cycle is long, total effective rate is low, Absorption And Metabolism is poor, and therapeutic efficiency and alimentation situation therefore how to improve uric acid resisting product have become current problem demanding prompt solution.
Summary of the invention
For solving the deficiencies in the prior art, the object of this invention is to provide a kind of composition and use thereof of uric acid resisting.The compositions of uric acid resisting provided by the invention selects raw-food material, reasonable formula, uric acid resisting Be very effective.
For reaching this object, the present invention is achieved by the following technical solutions:
First aspect, the invention provides a kind of compositions of uric acid resisting, and described compositions contains the oligomeric Gly-His-Lys of marine fish, leaf of Moringa powder, Malpighia glabra L. concentrate and plum extract.
" containing " of the present invention, mean it except described component, can also comprise other components, these other components give described compositions different characteristics.In addition, " containing " of the present invention, can also replace with enclosed " being " or " by ... composition ".
The oligomeric Gly-His-Lys of marine fish in the present invention can, purchased from Japanese Kiyatsu Aquatic Product Chemical Co., Ltd., be that refining and process, is a kind of batching of novel nutritious and healthy food with the skin of pollution-free or that pollution is relatively little bathypelagic fish, bone for raw material; Their overwhelming majority are made up of 2-6 aminoacid, molecular weight concentrates on 200-1000 daltonian micromolecule hybrid peptide class, directly can be absorbed by small intestinal, human body skin etc.
Leaf of Moringa powder in the present invention can, purchased from Guangzhou Neng Jing Bioisystech Co., Ltd, be formed through micronizing by the tender leaf of Moringa of selected children; It is rich in several mineral materials, vitamin, 20 seed amino acids, 46 kinds of antioxygen elements and 36 kinds of naturally anti-scorching bodies and mineral; There is the effects such as blood sugar lowering, blood fat reducing, blood pressure lowering, antitumor, antioxidation, relieving constipation, diuresis, anthelmintic, improving water flood, long-term eating can strengthen immune function of human body, slow down aging, to prevent disease, have good effect to hypertension, hyperlipidemia, diabetes, gout etc. especially.
Malpighia glabra L. concentrate in the present invention can, purchased from upper Haicheng one raw-food material company limited, be the extract of Malpighia glabra L., and Malpighia glabra L. is the Chinese appellation of A Xi roller Fructus Pruni pseudocerasi (Acerolacherry); Because Malpighia glabra L. is rich in vitamin C, be the current known fruit the abundantest containing vitamin C in the world; Malpighia glabra L. is also containing vitamin A, B simultaneously
1, B
2, E, P, niacin, the defying age factor (SOD), calcium, ferrum, zinc, the multiple nutrients material such as potassium and protein, high nutritive value.
Plum extract in the present invention can purchased from Beijing Sheng Lun Food Co., Ltd, and plum extract contains the organic acid such as abundant citric acid and malic acid and multivitamin and mineral, can alleviate, allaying tiredness; Also containing the material such as flavone glycoside, triterpene saponin, polyphenol and alkene, having calms the nerves separates tired and antitumor, remove blood rubbish, slow down aging, antibacterial, fat-reducing and hair growth promoting effect.
The present invention adopts oligomeric for marine fish Gly-His-Lys, leaf of Moringa powder, Malpighia glabra L. concentrate and plum extract to carry out being combined to form compositions.Experiment proves, the oligomeric Gly-His-Lys of marine fish can control rapidly Uric Acid level, alleviate inflammation and pain; Leaf of Moringa powder has the effect such as antiinflammatory, diuresis, promotes that uric acid excretes; Plum extract can improve body immunity, reduces uric acid in blood content; Malpighia glabra L. concentrate can regulate sleep, anti-inflammatory and antalgic.Synergism between these 4 kinds of components, makes the successful of described compositions uric acid resisting be better than single or two or three kind of feedstock composition, and patient can be made to take this uric acid resisting compositions after 8 weeks, and the effective percentage of uric acid resisting reaches more than 97%, and has no side effect.
In the present invention, described compositions by weight percentage composition containing, for example lower raw material components: the oligomeric Gly-His-Lys 5-35% of marine fish, leaf of Moringa powder 5-45%, Malpighia glabra L. concentrate 2-15%, plum extract 5-30%.
The present invention is according to compositions uric acid resisting effect, and the content proportioning of each raw material in optimum organization thing, makes each component play the effect of uric acid resisting to a greater degree.
Further improve as the present invention, described compositions by weight percentage composition containing, for example lower raw material components: the oligomeric Gly-His-Lys 5-35% of marine fish, leaf of Moringa powder 5-45%, Malpighia glabra L. concentrate 2-15%, plum extract 5-30%, surplus is edible adjuvant.
" surplus " of the present invention just reaches 100% for the content meeting described compositions.That is, only have when described raw material components does not meet 100%, " surplus " herein means various edible adjuvant, and the content being supplied to realize described compositions by this edible adjuvant component is 100%; If described raw material components sum reaches 100%, then without the need to adding edible adjuvant.No matter which kind of composition is compositions of the present invention comprise, and the weight percentage sum of described compositions is 100%.
In compositions of the present invention, weight percentage shared by the oligomeric Gly-His-Lys of described marine fish is 5-35%, can be such as 5%, 6%, 7%, 8%, 10%, 12%, 15%, 18%, 20%, 22%, 25%, 28%, 30%, 32%, 35%, be preferably 10-30%, more preferably 25-30%.
In compositions of the present invention, weight percentage shared by described leaf of Moringa powder is 5-45%, can be such as 5%, 6%, 7%, 8%, 10%, 12%, 15%, 18%, 20%, 22%, 25%, 28%, 30%, 32%, 35%, 38%, 40%, 42%, 45%, be preferably 15-25%, more preferably 15-20%.
In compositions of the present invention, weight percentage shared by described Malpighia glabra L. concentrate is 2-15%, can be such as 2%, 3%, 4%, 5%, 6%, 8%, 10%, 11%, 12%, 13%, 14%, 15%, be preferably 4-12%, more preferably 8-10%.
In compositions of the present invention, weight percentage shared by described plum extract is 5-30%, can be such as 5%, 6%, 7%, 8%, 10%, 12%, 15%, 18%, 20%, 22%, 25%, 28%, 30%, be preferably 5-15%, more preferably 10-15%.
As further improvement of the present invention, described compositions by weight percentage composition is made up of following raw material components: the oligomeric Gly-His-Lys 10-30% of marine fish, leaf of Moringa powder 10-25%, Malpighia glabra L. concentrate 4-12%, plum extract 5-15%, surplus is edible adjuvant.
As further improvement of the present invention, described compositions by weight percentage composition is made up of following raw material components: the oligomeric Gly-His-Lys 25-30% of marine fish, leaf of Moringa powder 15-20%, Malpighia glabra L. concentrate 8-10%, plum extract 10-15%, surplus is edible adjuvant.
The compositions of uric acid resisting of the present invention can comprise by percentage composition by weight: the oligomeric Gly-His-Lys 5-35% of marine fish, leaf of Moringa powder 5-45%, Malpighia glabra L. concentrate 2-15%, plum extract 5-30%, further, by being optimized the content proportioning of raw material each in said composition, find that uric acid resisting compositions of the present invention at the weight percentage of each raw material components is: the oligomeric Gly-His-Lys 25-30% of marine fish, leaf of Moringa powder 15-20%, Malpighia glabra L. concentrate 8-10%, under the proportioning of plum extract 10-15%, compare each component of the present invention when the value of other content, best uric acid resisting effect can be reached.
Edible adjuvant in the present invention is food stage adjuvant, comprises the food additive such as excipient, stabilizing agent, flavour enhancer, colour fixative, is not particularly limited at this.Its object of adding is, the various dosage form taken or the consumer demand meeting different taste hobby are convenient in preparation.
Second aspect, present invention also offers a kind of Chinese medicine preparation, and described Chinese medicine preparation contains compositions as described in relation to the first aspect.
The dosage form of preparation of the present invention can be tablet, capsule, powder, pill or granule etc., is not particularly limited at this, and it can be determined according to the needs of actual production and consumer demand.
The third aspect, present invention also offers compositions according to first aspect for the application in the health product of uric acid resisting, food or medicine.
Compared with prior art, the present invention at least has following beneficial effect:
The present invention with the oligomeric Gly-His-Lys of marine fish, leaf of Moringa powder, Malpighia glabra L. concentrate and plum extract for Effect raw material, scientific compatibility, synergism has been played between each component, reasonably combined edible adjuvant, can be made into health product or Chinese medicine preparation etc. such as having remarkable uric acid resisting effect, tablet, hard capsule, powder, this has the compositions of the effect of remarkable uric acid resisting, and patient can be made to take this uric acid resisting compositions after 8 weeks, the effective percentage of uric acid resisting can reach more than 97%, and has no side effect.
Detailed description of the invention
Technical scheme of the present invention is further illustrated below by detailed description of the invention.
Those skilled in the art should understand, described embodiment is only help to understand the present invention, should not be considered as concrete restriction of the present invention.
Embodiment 1: a kind of compositions of uric acid resisting
(1) composition tablet is prepared
Formula: the oligomeric Gly-His-Lys 25wt% of marine fish, leaf of Moringa powder 20wt%, Malpighia glabra L. concentrate 10wt%, plum extract 15wt%, edible adjuvant 30wt%.
Film-making agent: take raw material by above-mentioned formula, mix homogeneously, makes the tablet of 0.6g/ sheet.
(2) efficacy validation test
Patient data: patient 198 example, wherein male 120 example, age distribution 39-77 year; Women 78 example, age distribution 53-74 year.
Diagnostic criteria: patient articular's pain, night-time attack, is difficult to fall asleep; Blood uric acid increases, and male is higher than 6.0mg/dL, and women is higher than 5.0mg/dL; There is tophus.
Instructions of taking: every day 2 times, sooner or later respectively once, takes 2 months continuously by each 2.
Efficacy assessments standard: cure: lab testing Level of Serum Uric Acid is normal, symptoms of joint pain disappears, and tophus is removed; Take a turn for the better: lab testing Level of Serum Uric Acid reduces, and arthroncus is disappeared, pain relief, and tophus obviously reduces; Invalid: lab testing Level of Serum Uric Acid and symptom unchanged, tophus is unchanged.
Result of the test is as shown in table 1.
Table 1
As shown in Table 1, take the uric acid resisting compositions of the present embodiment after 6 weeks, patient's blood uric acid of 69% recovers normal, and patient's blood uric acid of 27% obviously reduces, and uric acid resisting effective percentage reaches 96%; Take the uric acid resisting compositions of the present embodiment after 8 weeks, patient's blood uric acid of 90% recovers normal, and patient's blood uric acid of 7% obviously reduces, and uric acid resisting effective percentage reaches 97%.
Embodiment 2: a kind of compositions of uric acid resisting
(1) compositions powder is prepared
Formula: the oligomeric Gly-His-Lys 10wt% of marine fish, leaf of Moringa powder 10wt%, Malpighia glabra L. concentrate 8wt%, plum extract 10wt%, edible adjuvant 62wt%.
Powder process agent: take raw material by above-mentioned formula, mix homogeneously, makes the powder of 2g/ bag.
(2) efficacy validation test
Patient data: patient 173 example, wherein male 106 example, age distribution 42-73 year; Women 67 example, age distribution 50-71 year.
Diagnostic criteria: patient articular's pain, night-time attack, is difficult to fall asleep; Blood uric acid increases, and male is higher than 6.0mg/dL, and women is higher than 5.0mg/dL; There is tophus.
Instructions of taking: every day 2 times, sooner or later respectively once, takes 2 months continuously by each 1 bag.
Efficacy assessments standard: cure: lab testing Level of Serum Uric Acid is normal, symptoms of joint pain disappears, and tophus is removed; Take a turn for the better: lab testing Level of Serum Uric Acid reduces, and arthroncus is disappeared, pain relief, and tophus obviously reduces; Invalid: lab testing Level of Serum Uric Acid and symptom unchanged, tophus is unchanged.
Result of the test is as shown in table 2.
Table 2
As shown in Table 2, take the uric acid resisting compositions of the present embodiment after 6 weeks, patient's blood uric acid of 64% recovers normal, and patient's blood uric acid of 20% obviously reduces, and uric acid resisting effective percentage reaches 84%; Take the uric acid resisting compositions of the present embodiment after 8 weeks, patient's blood uric acid of 82% recovers normal, and patient's blood uric acid of 8% obviously reduces, and uric acid resisting effective percentage reaches 90%.
Embodiment 3: a kind of compositions of uric acid resisting
(1) compositions hard capsule is prepared
Formula: the oligomeric Gly-His-Lys 30wt% of marine fish, leaf of Moringa powder 15wt%, Malpighia glabra L. concentrate 10wt%, plum extract 10wt%, edible adjuvant 35wt%.
Hard capsule processed: take raw material by above-mentioned formula, mix homogeneously, makes the hard capsule of 0.5g/ grain.
(2) efficacy validation test
Patient data: patient 181 example, wherein male 101 example, age distribution 40-69 year; Women 80 example, age distribution 51-73 year.
Diagnostic criteria: patient articular's pain, night-time attack, is difficult to fall asleep; Blood uric acid increases, and male is higher than 6.0mg/dL, and women is higher than 5.0mg/dL; There is tophus.
Instructions of taking: every day 2 times, sooner or later respectively once, takes 2 months continuously by each 2.
Efficacy assessments standard: cure: lab testing Level of Serum Uric Acid is normal, symptoms of joint pain disappears, and tophus is removed; Take a turn for the better: lab testing Level of Serum Uric Acid reduces, and arthroncus is disappeared, pain relief, and tophus obviously reduces; Invalid: lab testing Level of Serum Uric Acid and symptom unchanged, tophus is unchanged.
Result of the test is as shown in table 3.
Table 3
As shown in Table 3, take the uric acid resisting compositions of the present embodiment after 6 weeks, patient's blood uric acid of 61% recovers normal, and patient's blood uric acid of 24% obviously reduces, and uric acid resisting effective percentage reaches 85%; Take the uric acid resisting compositions of the present embodiment after 8 weeks, patient's blood uric acid of 83% recovers normal, and patient's blood uric acid of 12% obviously reduces, and uric acid resisting effective percentage reaches 95%.
Embodiment 4: a kind of compositions of uric acid resisting
(1) compositions hard capsule is prepared
Formula: the oligomeric Gly-His-Lys 25wt% of marine fish, leaf of Moringa powder 20wt%, edible adjuvant 55wt%.
Hard capsule processed: take raw material by above-mentioned formula respectively, mix homogeneously, makes the hard capsule of 0.5g/ grain.
(2) efficacy validation test
Patient data: patient 154 example, wherein male 86 example, age distribution 41-65 year; Women 68 example, age distribution 50-65 year.
Diagnostic criteria: patient articular's pain, night-time attack, is difficult to fall asleep; Blood uric acid increases, and male is higher than 6.0mg/dL, and women is higher than 5.0mg/dL; There is tophus.
Instructions of taking: every day 2 times, sooner or later respectively once, takes 2 months continuously by each 2.
Efficacy assessments standard: cure: lab testing Level of Serum Uric Acid is normal, symptoms of joint pain disappears, and tophus is removed; Take a turn for the better: lab testing Level of Serum Uric Acid reduces, and arthroncus is disappeared, pain relief, and tophus obviously reduces; Invalid: lab testing Level of Serum Uric Acid and symptom unchanged, tophus is unchanged.
Result of the test is as shown in table 4.
Table 4
As shown in Table 4, take the uric acid resisting compositions of the present embodiment after 6 weeks, patient's blood uric acid of 54% recovers normal, and patient's blood uric acid of 17% obviously reduces, and uric acid resisting effective percentage reaches 71%; Take the uric acid resisting compositions of the present embodiment after 8 weeks, patient's blood uric acid of 63% recovers normal, and patient's blood uric acid of 19% obviously reduces, and uric acid resisting effective percentage reaches 82%.
Embodiment 5: a kind of compositions of uric acid resisting
(1) compositions hard capsule is prepared
Formula: the oligomeric Gly-His-Lys 25wt% of marine fish, leaf of Moringa powder 20wt%, Malpighia glabra L. concentrate powder 10%, edible adjuvant 45wt%.
Hard capsule processed: take raw material by above-mentioned formula respectively, mix homogeneously, makes the hard capsule of 0.5g/ grain.
(2) efficacy validation test
Patient data: patient 163 example, wherein male 87 example, age distribution 43-69 year; Women 76 example, age distribution 47-71 year.
Diagnostic criteria: patient articular's pain, night-time attack, is difficult to fall asleep; Blood uric acid increases, and male is higher than 6.0mg/dL, and women is higher than 5.0mg/dL; There is tophus.
Instructions of taking: every day 2 times, sooner or later respectively once, takes 2 months continuously by each 2.
Efficacy assessments standard: cure: lab testing Level of Serum Uric Acid is normal, symptoms of joint pain disappears, and tophus is removed; Take a turn for the better: lab testing Level of Serum Uric Acid reduces, and arthroncus is disappeared, pain relief, and tophus obviously reduces; Invalid: lab testing Level of Serum Uric Acid and symptom unchanged, tophus is unchanged.
Result of the test is as shown in table 5.
Table 5
As shown in Table 5, take the uric acid resisting compositions of the present embodiment after 6 weeks, patient's blood uric acid of 56% recovers normal, and patient's blood uric acid of 19% obviously reduces, and uric acid resisting effective percentage reaches 75%; Take the uric acid resisting compositions of the present embodiment after 8 weeks, patient's blood uric acid of 67% recovers normal, and patient's blood uric acid of 20% obviously reduces, and uric acid resisting effective percentage reaches 87%.
Embodiment 6: a kind of compositions of uric acid resisting
(1) composition tablet is prepared
Formula: the oligomeric Gly-His-Lys 5wt% of marine fish, leaf of Moringa powder 45wt%, Malpighia glabra L. concentrate 2wt%, plum extract 5wt%, edible adjuvant 43wt%.
Film-making agent: take raw material by above-mentioned formula, mix homogeneously, makes the tablet of 0.6g/ sheet.
(2) efficacy validation test
107 routine patients, took the uric acid resisting compositions of the present embodiment after 8 weeks, and patient's blood uric acid of 27% recovers normal, and patient's blood uric acid of 18% obviously reduces, and uric acid resisting effective percentage reaches 45%.
Embodiment 7: a kind of compositions of uric acid resisting
(1) composition tablet is prepared
Formula: the oligomeric Gly-His-Lys 35wt% of marine fish, leaf of Moringa powder 5wt%, Malpighia glabra L. concentrate 15wt%, plum extract 15wt%, edible adjuvant 30wt%.
Film-making agent: take raw material by above-mentioned formula, mix homogeneously, makes the tablet of 0.6g/ sheet.
(2) efficacy validation test
110 routine patients, took the uric acid resisting compositions of the present embodiment after 8 weeks, and patient's blood uric acid of 44% recovers normal, and patient's blood uric acid of 29% obviously reduces, and uric acid resisting effective percentage reaches 73%.
Embodiment 8: a kind of compositions of uric acid resisting
(1) compositions powder is prepared
Formula: the oligomeric Gly-His-Lys 22wt% of marine fish, leaf of Moringa powder 30wt%, Malpighia glabra L. concentrate 5wt%, plum extract 6wt%, edible adjuvant 37wt%.
Powder process agent: take raw material by above-mentioned formula, mix homogeneously, makes the powder of 2g/ bag.
(2) efficacy validation test
98 routine patients, took the uric acid resisting compositions of the present embodiment after 8 weeks, and patient's blood uric acid of 51% recovers normal, and patient's blood uric acid of 25% obviously reduces, and uric acid resisting effective percentage reaches 76%.
Embodiment 9: a kind of compositions of uric acid resisting
(1) compositions powder is prepared
Formula: the oligomeric Gly-His-Lys 32wt% of marine fish, leaf of Moringa powder 8wt%, Malpighia glabra L. concentrate 15wt%, plum extract 30wt%, edible adjuvant 15wt%.
Powder process agent: take raw material by above-mentioned formula, mix homogeneously, makes the powder of 2g/ bag.
(2) efficacy validation test
101 routine patients, took the uric acid resisting compositions of the present embodiment after 8 weeks, and patient's blood uric acid of 49% recovers normal, and patient's blood uric acid of 23% obviously reduces, and uric acid resisting effective percentage reaches 72%.
Embodiment 10: a kind of compositions of uric acid resisting
(1) compositions hard capsule is prepared
Formula: the oligomeric Gly-His-Lys 15wt% of marine fish, leaf of Moringa powder 25wt%, Malpighia glabra L. concentrate 10wt%, plum extract 25wt%, edible adjuvant 25wt%.
Hard capsule processed: take raw material by above-mentioned formula, mix homogeneously, makes the hard capsule of 0.5g/ grain.
(2) efficacy validation test
97 routine patients, took the uric acid resisting compositions of the present embodiment after 8 weeks, and patient's blood uric acid of 44% recovers normal, and patient's blood uric acid of 25% obviously reduces, and uric acid resisting effective percentage reaches 69%.
Embodiment 11: a kind of compositions of uric acid resisting
(1) compositions hard capsule is prepared
Formula: the oligomeric Gly-His-Lys 12wt% of marine fish, leaf of Moringa powder 30wt%, Malpighia glabra L. concentrate 8wt%, plum extract 15wt%, edible adjuvant 35wt%.
Hard capsule processed: take raw material by above-mentioned formula, mix homogeneously, makes the hard capsule of 0.5g/ grain.
(2) efficacy validation test
107 routine patients, took the uric acid resisting compositions of the present embodiment after 8 weeks, and patient's blood uric acid of 38% recovers normal, and patient's blood uric acid of 26% obviously reduces, and uric acid resisting effective percentage reaches 64%.
Can be found out by above embodiment, the present invention carries out rational proportion with the oligomeric Gly-His-Lys of marine fish, leaf of Moringa powder, Malpighia glabra L. concentrate and plum extract for Effect raw material, scientific compatibility, synergism has been played between each component, reasonably combined edible adjuvant, can be made into and there is remarkable uric acid resisting effect and health product or the Chinese medicine preparation etc. such as the tablet had no side effect, hard capsule, powder, this has the compositions of the effect of remarkable uric acid resisting, patient can be made to take this uric acid resisting compositions after 8 weeks, and the effective percentage of uric acid resisting can reach more than 97%.
Applicant states, the present invention illustrates process of the present invention by above-described embodiment, but the present invention is not limited to above-mentioned processing step, does not namely mean that the present invention must rely on above-mentioned processing step and could implement.Person of ordinary skill in the field should understand, any improvement in the present invention, to equivalence replacement and the interpolation of auxiliary element, the concrete way choice etc. of raw material selected by the present invention, all drops within protection scope of the present invention and open scope.
Claims (8)
1. a compositions for uric acid resisting, is characterized in that, described compositions contains the oligomeric Gly-His-Lys of marine fish, leaf of Moringa powder, Malpighia glabra L. concentrate and plum extract.
2. compositions according to claim 1, is characterized in that, described compositions by weight percentage composition containing, for example lower raw material components: the oligomeric Gly-His-Lys 5-35% of marine fish, leaf of Moringa powder 5-45%, Malpighia glabra L. concentrate 2-15%, plum extract 5-30%.
3. compositions according to claim 1 and 2, it is characterized in that, described compositions by weight percentage composition containing, for example lower raw material components: the oligomeric Gly-His-Lys 10-30% of marine fish, leaf of Moringa powder 10-25%, Malpighia glabra L. concentrate 4-12%, plum extract 5-15%.
4. the compositions according to any one of claim 1-3, it is characterized in that, described compositions by weight percentage composition containing, for example lower raw material components: the oligomeric Gly-His-Lys 25-30% of marine fish, leaf of Moringa powder 15-20%, Malpighia glabra L. concentrate 8-10%, plum extract 10-15%.
5. the compositions according to any one of claim 1-4, is characterized in that, described compositions is also containing edible adjuvant;
Preferably, described edible adjuvant is the mixture of any one or at least two kinds in excipient, stabilizing agent, flavour enhancer or colour fixative.
6. a Chinese medicine preparation, is characterized in that, described Chinese medicine preparation is containing, for example the compositions described in any one of claim 1-5.
7. Chinese medicine preparation according to claim 6, is characterized in that, the dosage form of described preparation is tablet, capsule, powder, pill or granule.
8. the compositions according to any one of claim 1-5 is for the application in the health product of uric acid resisting, food or medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510642189.9A CN105126067B (en) | 2015-09-30 | 2015-09-30 | A kind of composition of anti-trioxypurine and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510642189.9A CN105126067B (en) | 2015-09-30 | 2015-09-30 | A kind of composition of anti-trioxypurine and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105126067A true CN105126067A (en) | 2015-12-09 |
| CN105126067B CN105126067B (en) | 2018-05-22 |
Family
ID=54711878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510642189.9A Active CN105126067B (en) | 2015-09-30 | 2015-09-30 | A kind of composition of anti-trioxypurine and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105126067B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107951022A (en) * | 2017-12-28 | 2018-04-24 | 陆淼兴 | A kind of marine fish oligopeptide mixture and its preparation and preparation method |
| CN108185434A (en) * | 2018-01-19 | 2018-06-22 | 长江师范学院 | A kind of health food for preventing hyperuricemia and gout |
| CN109122859A (en) * | 2018-11-01 | 2019-01-04 | 威海健康生生物科技有限公司 | Anti-trioxypurine composition and the preparation method and application thereof |
| CN109172806A (en) * | 2018-11-07 | 2019-01-11 | 张玉龙 | A kind of composition and preparation method thereof reducing uric acid level |
| CN109567070A (en) * | 2018-12-12 | 2019-04-05 | 海南热带海洋学院 | A kind of acerola concentrate sea cucumber composite chewable tablet and preparation method thereof |
| CN110038119A (en) * | 2019-04-28 | 2019-07-23 | 杭州泽健医药科技有限公司 | A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect |
| CN111617231A (en) * | 2019-11-01 | 2020-09-04 | 北京同仁堂健康药业股份有限公司 | Uric acid-reducing and anti-gout composition as well as preparation method and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1572318A (en) * | 2003-05-30 | 2005-02-02 | 利统股份有限公司 | Composition containing dipeptide of histidine and alanine for reducing uric acid |
| CN101190280A (en) * | 2006-11-27 | 2008-06-04 | 杭州尤美特科技有限公司 | Use of extract of non-fruit part of prune tree |
| CN103637105A (en) * | 2013-11-26 | 2014-03-19 | 郑州韩都药业集团有限公司 | Cherry capsule |
| CN103735741A (en) * | 2014-01-23 | 2014-04-23 | 李文东 | Traditional Chinese medicinal composition for treating gout |
| CN104758325A (en) * | 2015-04-03 | 2015-07-08 | 萧丽雅 | Extraction method and application of moringa oleifera leaf total flavones |
| CN104758920A (en) * | 2015-04-29 | 2015-07-08 | 唐凯 | Gout health care product based on homology of medicine and food |
| CN104829743A (en) * | 2015-05-25 | 2015-08-12 | 萧丽雅 | Preparation method and use of moringa oleifera leaf polysaccharides |
| CN104886581A (en) * | 2015-06-18 | 2015-09-09 | 上海善力健生物科技有限公司 | Biological agent for decreasing uric acid, treating gout and eliminating overnutrition and preparation method of biological agent |
-
2015
- 2015-09-30 CN CN201510642189.9A patent/CN105126067B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1572318A (en) * | 2003-05-30 | 2005-02-02 | 利统股份有限公司 | Composition containing dipeptide of histidine and alanine for reducing uric acid |
| CN101190280A (en) * | 2006-11-27 | 2008-06-04 | 杭州尤美特科技有限公司 | Use of extract of non-fruit part of prune tree |
| CN103637105A (en) * | 2013-11-26 | 2014-03-19 | 郑州韩都药业集团有限公司 | Cherry capsule |
| CN103735741A (en) * | 2014-01-23 | 2014-04-23 | 李文东 | Traditional Chinese medicinal composition for treating gout |
| CN104758325A (en) * | 2015-04-03 | 2015-07-08 | 萧丽雅 | Extraction method and application of moringa oleifera leaf total flavones |
| CN104758920A (en) * | 2015-04-29 | 2015-07-08 | 唐凯 | Gout health care product based on homology of medicine and food |
| CN104829743A (en) * | 2015-05-25 | 2015-08-12 | 萧丽雅 | Preparation method and use of moringa oleifera leaf polysaccharides |
| CN104886581A (en) * | 2015-06-18 | 2015-09-09 | 上海善力健生物科技有限公司 | Biological agent for decreasing uric acid, treating gout and eliminating overnutrition and preparation method of biological agent |
Non-Patent Citations (2)
| Title |
|---|
| 于建伟 等: "青梅提取物改善痛风和高尿酸血症的研究", 《食品工业科技》 * |
| 马玲 等: "高尿酸血症与膳食营养", 《现代预防医学》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107951022A (en) * | 2017-12-28 | 2018-04-24 | 陆淼兴 | A kind of marine fish oligopeptide mixture and its preparation and preparation method |
| CN108185434A (en) * | 2018-01-19 | 2018-06-22 | 长江师范学院 | A kind of health food for preventing hyperuricemia and gout |
| CN109122859A (en) * | 2018-11-01 | 2019-01-04 | 威海健康生生物科技有限公司 | Anti-trioxypurine composition and the preparation method and application thereof |
| CN109172806A (en) * | 2018-11-07 | 2019-01-11 | 张玉龙 | A kind of composition and preparation method thereof reducing uric acid level |
| CN109567070A (en) * | 2018-12-12 | 2019-04-05 | 海南热带海洋学院 | A kind of acerola concentrate sea cucumber composite chewable tablet and preparation method thereof |
| CN110038119A (en) * | 2019-04-28 | 2019-07-23 | 杭州泽健医药科技有限公司 | A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect |
| CN111617231A (en) * | 2019-11-01 | 2020-09-04 | 北京同仁堂健康药业股份有限公司 | Uric acid-reducing and anti-gout composition as well as preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105126067B (en) | 2018-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105126067A (en) | Composition for reducing uric acid and application thereof | |
| KR101090284B1 (en) | Tonic comprising red ginseng and deer antlers extracts and manufacturing method thereof | |
| CN102640829B (en) | Tea paste with myocardial ischemia function improving function and preparation method of tea paste | |
| CN103622030A (en) | Constipation dietotherapy composition and preparation method thereof | |
| CN103238798A (en) | Dendrobium nutrient tablet and preparation method | |
| CN104189035A (en) | Health-care food with function of enhancing body immunity, and preparation method thereof | |
| CN101297889A (en) | Chinese medicine preparation for treating foot-and-mouth disease and preparation method thereof | |
| CN104667135A (en) | Pharmaceutical composition and health care product and preparation method | |
| CN102526346B (en) | Health-care pharmaceutical formulation with immunity-enhancing and senility-delaying functions | |
| CN103355444B (en) | A kind of invigorating the spleen qi-tonifying health-care tea cream and preparation method | |
| CN103610076A (en) | Preparation method for sea cucumber capsule | |
| CN103920135B (en) | A kind of Thallus Laminariae (Thallus Eckloniae) amino composite sheet reducing uric acid content and preparation method thereof | |
| CN104667109A (en) | Pharmaceutical composition and health care product and preparation method | |
| CN105250747A (en) | Health maintenance paste | |
| CN106010849A (en) | SOD (superoxide dismutase) wine | |
| KR20160010909A (en) | Natural beauty soap for the improvement and treatment of the Eczema.acne, psoriasis, seborrheic skin using White Ionic Minerals, SY2220, and White Ionic Minerals distilled water, SY2216, extracted from white clay of Yang Gu Bangsan region and manufacturing method and that compositions. | |
| KR20140115747A (en) | pill manufacture method using palm tree fruit | |
| KR100634289B1 (en) | Supplemantary Material and Manufacturing Method of the Same for Improving Physical Constitution of Atopy Dermatitis Patients | |
| KR20090099141A (en) | Composition for health beverage using barley sprout | |
| CN106138968A (en) | Integration of edible and medicinal herbs compositions of the intestines and stomach reparation and protection gastrointestinal mucosa and preparation method thereof | |
| CN105687808A (en) | Rhizome bletillae oral liquid capable of stopping bleeding by astringency, and production method thereof | |
| CN105876542A (en) | Aloe vera containing vinegar drink | |
| CN105249448A (en) | Moringa oleifera stomach-strengthening composition and preparation method thereof | |
| CN103783479A (en) | Brain tonifying and invigorating sarcodon aspratus hot pot condiment and production method thereof | |
| CN117244028A (en) | Composition for alcoholic liver disease and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 102200 Beijing science and Technology Park of Changping District Bai Fu Road 13 Applicant after: BEIJING ZHI FENG TANG HEALTH TECHNOLOGY CO., LTD. Address before: 102200 Beijing science and Technology Park of Changping District Bai Fu Road 13 Applicant before: Beijing Zhifengtang Bee Product Co., Ltd. |
|
| COR | Change of bibliographic data | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Yuqiang Inventor after: Huang Jidong Inventor after: Song Guilin Inventor after: Yang Ajing Inventor before: Li Yuqiang Inventor before: Huang Yidong Inventor before: Song Guilin Inventor before: Yang Ajing |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |